argenx shares are trading higher after the company announced an FDA approval that expands VYVGART and VYVGART Hytrulo label to treat all serotypes of generalized myasthenia gravis.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!